Abstract Background Central nervous system (CNS) complications are increasingly noted in liver transplanted (LTx) hereditary transthyretin amyloid (ATTRm) amyloidosis patients; this suggests that the increased survival allows for intracranial ATTRm formation from brain synthesised mutant TTR. However, atrial fibrillation (AF), a recognised risk factor for ischemic CNS complications, is also observed after LTx. The aim of the study was to investigate the occurrence of CNS complications and AF in LTx ATTRm amyloidosis patients. Methods The medical records of all LTx ATTRm amyloidosis patients in the county of Västerbotten, Sweden were investigated for information on CNS complications, AF, anticoagulation (AC) therapy, hypertension, cardiac ischemic disease, hypertrophy, and neurological status. Results Sixty-three patients that had survived for three years or longer after LTx were included in the analysis. Twenty-five patients had developed 1 or more CNS complications at a median of 21 years after onset of disease. AF was noted in 21 patients (median time to diagnosis 24 years). Cerebrovascular events (CVE) developed in 17 (median time to event 21 years). CVEs occurred significantly more often in patients with AF (P<0.002). AC therapy significantly reduced CVEs, including bleeding in patients with AF (P=0.04). Multivariate analysis identified AF as the only remaining regressor with a significant impact on CVE (HR 3.8; 95% CI 1.1 – 9.5; P= 0.029) Conclusions AF is an important risk factor for CVE in LTx ATTRm amyloidosis patients, and AC therapy should be considered. However the increased bleeding risk with AC therapy in patients with intracranial amyloidosis should be acknowledged.
Transplantation – Wolters Kluwer Health
Published: Nov 1, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud